Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron‐containing medicines
Fernando Gomollón(Universidad de Zaragoza), Walter Reinisch(Medical University of Vienna), Bjørn Moum(University of Oslo), Axel Dignaß(Goethe University Frankfurt), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), Yehuda Chowers(Cleveland Clinic), Péter L. Lakatos(McGill University), Murat Törüner(Ankara University), Pierre Michetti(University of Bern), Herman Stoevelaar(Barnes-Jewish Hospital), G. Mantzaris(Evangelismos Hospital), Charlie W. Lees(Western General Hospital), C. Janneke van der Woude(Radboud University Nijmegen), Stefan Lindgren(Skåne University Hospital), Ole Haagen Nielsen(University of Copenhagen)
Cited by 10
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k